Thus, DIO’s therapeutic efficacy in DN may arise from its concurrent targeting of NLRP3-driven renal fibrosis and gut barrier preservation, highlighting the interconnectedness of mucosal immunity and chronic kidney disease pathogenesis. The gene discussed is NLRP3; the disease is renal fibrosis.